Irene Saulnier’s Post

FIRST fund is thrilled to celebrate that TargED Biopharmaceuticals is dosing the first participant in their Phase 1 clinical trial of TGD001—a groundbreaking thrombolytic treatment. This is not just a milestone for TargED, but also a first for the FIRST Fund: the first portfolio company to enter the clinic. From the early days of supporting TargED’s vision, FIRST Fund has been privileged to witness their transformation from academic research—initially supported by the Hartstichting - Dutch Heart Foundation - into a clinical-stage company. Seeing their innovation now poised to potentially transform the treatment of thrombotic disorders, including acute ischemic stroke (AIS) and iTTP, is both inspiring and rewarding. Congratulations to the TargED team for achieving this milestone and for leading the way as a FIRST Fund portfolio company entering the clinic. We look forward to continuing this journey together! #Innovation #Biotech #Thrombosis #ClinicalTrials #FIRSTFund #TargEDBiopharma Read the details using the following link: https://lnkd.in/e5FXhKEX #lifesciences #biotech #thrombolytic

Building causal hypotheses in drug discovery 🎥🤔 If you missed last week's panel discussion with our own Nicola McCarthy and Namshik Han, and Biorelate's Ben Sidders and Daniel Jamieson, you can now view the recording online! Where are the opportunities to use AI and data driven approaches to create more robust models for developing actionable hypotheses? How can biopharma make better use of data for developing mechanistic rationales that will improve drug discovery outcomes for drug developers and patients? Join the discussion by clicking here 👉 https://lnkd.in/eZsq-25A

Following a truly insight-rich discussion last week with Nicola McCarthy and Namshik Han of the Milner Therapeutics Institute and Biorelate's CSO Ben Sidders, you can now access the recorded webinar >> https://lnkd.in/eZsq-25A #drugdiscovery #artificialintelligence #bioinformatics

🔬 Co-founder and CEO of YouthBio Therapeutics Inc., Yuri Deigin, shares the path that led him to establish a company focused on longevity research. 📽️ Watch his episode of Founders here. ⏩ https://bit.ly/FoundersE21

Sling’s oral Tepezza rival hits goal in thyroid eye disease, setting stage for confirmatory phase 3 https://lnkd.in/gpiX8ZQA Sling Therapeutics’ oral challenger to Amgen’s intravenous Tepezza has hit the mark in a phase 2b/3 thyroid eye disease trial, teeing the biotech up to run a confirmatory study of its ex-Astellas asset. But a [...] #LosAngeles #OrangeCountyCA #Biotech #Lifescience #News

Thryv Therapeutics Inc. will be hosting their very first “Ask Thryv Live” on Tuesday, May 7th from 12:00 p.m. to 1:00 p.m. ET. First Half: Updates & Insights Wave I Studies Update: Get insights into the progress of the Wave Studies. Advancements in Atrial Fibrillation Research: Plan for the clinical program. Series B Financing Status: An update on the second round of financing which will help move forward many exciting projects. Exploring New Frontiers: Discover the innovative research into SGK1 inhibition across various indications. Second Half: Interactive Q&A Pre-submit Questions: Email your questions in advance to admin@thryvtrx.com. Ask Live: Participate actively during the webinar by submitting anonymous questions in real-time. Note: this webinar will be recorded for internal purposes but will NOT be available to watch afterwards. Please register to view the webinar and learn more about the amazing work Thryv are doing! Give a like, share and register ❤️ https://lnkd.in/e-A-cznS

❗𝗪𝗔𝗥𝗡𝗜𝗡𝗚: 2 Discounted Passes Left for the 𝟲𝘁𝗵 𝗠𝗮𝗰𝗿𝗼𝗽𝗵𝗮𝗴𝗲-𝗗𝗶𝗿𝗲𝗰𝘁𝗲𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗦𝘂𝗺𝗺𝗶𝘁!   Time is running out to be part of the 𝗺𝗼𝘀𝘁 𝗰𝗿𝘂𝗰𝗶𝗮𝗹 𝗲𝘃𝗲𝗻𝘁 𝗶𝗻 𝗺𝗮𝗰𝗿𝗼𝗽𝗵𝗮𝗴𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀. Don't risk falling behind as top experts 𝗰𝗼𝗻𝗳𝗿𝗼𝗻𝘁 𝘁𝗵𝗲 𝗺𝗼𝘀𝘁 𝗽𝗿𝗲𝘀𝘀𝗶𝗻𝗴 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 and share their 𝘀𝗲𝗰𝗿𝗲𝘁𝘀 𝗼𝗻 𝗶𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁𝘀 𝗮𝗻𝗱 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽𝘀.   𝗚𝗿𝗮𝗯 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗼𝗴𝗿𝗮𝗺 - https://ter.li/ntamqp   Once these 2 passes are gone, so is your chance to stay ahead in this fast-evolving field.   ⏳ 𝗦𝗮𝘃𝗲 $𝟯𝟬𝟬 𝗯𝘆 𝗺𝗶𝗱𝗻𝗶𝗴𝗵𝘁 𝘁𝗼𝗺𝗼𝗿𝗿𝗼𝘄 - https://ter.li/ook4wg   Don't let this opportunity slip away!   #MacrophageDirectedTherapiesSummit

Join us for a recap of the recent presentation at Noble Capital's conference, where Cadrenal Therapeutics, Inc. (CVKD) was spotlighted. Our CEO, Quang Pham, along with Robert Leboyer, Senior Biotechnology Analyst at Noble Capital, and Doug Losordo, Chief Scientific Officer, shared insights into our innovative therapies for neurological disorders. With over 11 clinical trials and proven efficacy, Tecarfarin, our lead candidate, a novel oral anti-coagulant designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions, offers a stable anti-coagulation solution where existing options fall short. Stay tuned for trial initiations and regulatory updates as Cadrenal Therapeutics, Inc. (CVKD) advances towards FDA submission. #Cadrenal #Nasdaq #CVKD #Biotech #Innovation #Tecarfarin Cadrenal Therapeutics, Inc. - NOBLE Capital Markets Virtual Healthcare Conference Replay (youtube.com) - https://lnkd.in/d5mA_aHt

If you're looking to learn valuable tips for presenting science effectively, be sure to register for the webinar below ⤵

It's clear that the Annual Meeting is more than just a conference; it's a catalyst for sparking ideas, forming relationships, and advancing progress. As Joe Lewcock, Ph.D., Chief Scientific Officer of Denali Therapeutics, eloquently expressed, "I can see it's been incredibly impactful to be involved, not just through the consortia... but through the relationships we've built at this meeting." Together, we're driving groundbreaking advancements in ALS research. #ALSResearch #EveryoneLives #ALS #EndALS #ALSAwarenessMonth